Clene (NASDAQ:CLNN) Major Shareholder Sells $32,218.36 in Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 6,418 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $5.02, for a total transaction of $32,218.36. Following the completion of the sale, the insider directly owned 593,185 shares in the company, valued at $2,977,788.70. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
• On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total transaction of $21,026.12.
• On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total transaction of $29,280.12.
• On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The shares were sold at an average price of $5.32, for a total transaction of $67,377.80.
• On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total value of $61,200.95.
• On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total value of $59,673.60.
• On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The shares were sold at an average price of $5.13, for a total value of $40,644.99.
• On Thursday, January 15th, Chidozie Ugwumba sold 12,563 shares of Clene stock. The stock was sold at an average price of $5.10, for a total value of $64,071.30.
• On Wednesday, January 14th, Chidozie Ugwumba sold 19,621 shares of Clene stock. The shares were sold at an average price of $5.12, for a total value of $100,459.52.
• On Tuesday, January 13th, Chidozie Ugwumba sold 26,105 shares of Clene stock. The stock was sold at an average price of $4.89, for a total value of $127,653.45.

Clene Price Performance

Shares of Clene stock opened at $4.09 on Friday. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The firm’s 50-day moving average is $6.34 and its 200 day moving average is $6.52. The stock has a market cap of $44.38 million, a price-to-earnings ratio of -1.21 and a beta of 0.87.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, equities analysts expect that Clene Inc. will post -5.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on CLNN. Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. UBS Group reiterated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Benchmark restated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Clene in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.60.

Hedge Funds Weigh In On Clene

Several institutional investors have recently made changes to their positions in CLNN. Lunt Capital Management Inc. boosted its holdings in shares of Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after buying an additional 21,217 shares during the last quarter. Jane Street Group LLC bought a new position in Clene in the second quarter worth approximately $47,000. Scoggin Management LP grew its position in shares of Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after acquiring an additional 42,750 shares during the period. Finally, Jones Financial Companies Lllp bought a new stake in shares of Clene during the 3rd quarter valued at $29,000. Institutional investors own 23.28% of the company’s stock.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).